En bloc resection and hernia repair were performed. Histopathology confirmed well-differentiated liposarcoma (WDLS) with MDM2/CDK4 overexpression and MDM2 amplification via fluorescence in situ ...

The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

Version of Record: This is the final version of the article. García-Vázquez et al. identify GTSE1 as a novel target of the cyclin D1-CDK4/6 kinases. The authors show that GTSE1 is phosphorylated at ...

She’s now on a variety of drugs including injections that shut off her ovaries and another drug – an oral CDK4/6 inhibitor that helps stop cancer cells multiplying. It’s a lot for her to cop ...

The trial evaluated the efficacy of imlunestrant, an oral selective estrogen receptor degrader (SERD), compared with fulvestrant (Faslodex) in patients who had previously been treated with CDK4/6 ...

Meihua Li and Apeng Liang contributed equally to this work. FDA approved CDK4/6 inhibition medicines has demonstrated significant clinical benefits in patients with HR+/HER2- breast cancer. However, ...

CDK4/6 inhibitors (CDK4/6i) have revolutionized HR+ metastatic breast cancer treatment. Trials like PALOMA, MONALEESA, and MONARCH showed improved progression-free survival (PFS) with endocrine ...

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial The following ...